Zobrazeno 1 - 10
of 50
pro vyhledávání: '"H Geukens"'
Publikováno v:
Clinical Hemorheology and Microcirculation. 5:949-957
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39d44d5777f47c9e0d8b0cf7c9699000
https://doi.org/10.3233/ch-1985-5611
https://doi.org/10.3233/ch-1985-5611
Publikováno v:
Proceedings of the Royal Society of Medicine. 70(Suppl 8)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c40c7406da10c849657f0d02f5e92087
https://pubmed.ncbi.nlm.nih.gov/20919377
https://pubmed.ncbi.nlm.nih.gov/20919377
Publikováno v:
Drug Investigation. 3:40-50
Treatment with nebivolol, a novel β1-adrenergic antagonist, significantly improved left ventricular function, as measured by systolic time intervals (STIs) in normal volunteers, and in patients with essential hypertension, acute myocardial infarctio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45648703d11136ee7648060e3b5244e4
https://doi.org/10.1007/bf03258262
https://doi.org/10.1007/bf03258262
Publikováno v:
Angiology. 41:95-105
In an observer-blind four-way crossover study, 7 healthy volunteers received in random sequence, one month apart, atenolol 100 mg od, propranolol (slow release) 160 mg od, pindolol 5 mg tid, and nebivolol 5 mg od for a period of seven days, followed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4dadb35189338ecbe0b9bfea69dec57
https://doi.org/10.1177/000331979004100202
https://doi.org/10.1177/000331979004100202
Publikováno v:
International angiology : a journal of the International Union of Angiology. 12(1)
After a 1-month placebo run-in phase, 27 patients with proven peripheral arterial obstructive disease participated in a double blind placebo controlled study and were divided in 3 groups, receiving either placebo, ridogrel 300 mg b.i.d. (a combined t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::592527c34f631ea11e2f8cf2569b339d
https://pubmed.ncbi.nlm.nih.gov/8376914
https://pubmed.ncbi.nlm.nih.gov/8376914
Publikováno v:
Angiology: the journal of vascular diseases
Acute, subacute, and chronic treatment with nebivolol, a novel β1-selective adrenergic antagonist, significantly lowered systolic and diastolic blood pressure and heart rate in patients with essential hypertension. No orthostatism and bradycardia we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0074741483d026e96db6f888d64e4f4
https://hdl.handle.net/10067/37710151162165141
https://hdl.handle.net/10067/37710151162165141
Publikováno v:
International journal of clinical pharmacology research. 12(4)
Nebivolol is a novel selective beta 1-adrenergic antagonist with an unusual haemodynamic profile. It improves left ventricular function in normals and in patients with a damaged left ventricle. We compared the cardiac effects of a 14-day treatment pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d84cc24516db9aec83c60ae0063ed82d
https://pubmed.ncbi.nlm.nih.gov/1363660
https://pubmed.ncbi.nlm.nih.gov/1363660
Publikováno v:
Drug Investigation. 3:142-143
Nebivolol is a novel ,61-adrenergic antagonist with an unusual haemodynamic profile (Van de Water et al. 1988). In contrast to classical ,6-blocking agents, nebivolol improves left ventricular function as measured by systolic time intervals (STls) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca910c11a43aeb2b42ca104f6f8195d3
https://doi.org/10.1007/bf03258285
https://doi.org/10.1007/bf03258285
Publikováno v:
Drug Investigation. 3:140-141
50mg twice daily or nebivolol 5mg once daily, for a period of 9 days. A comparison of STIs in an age-matched control group of 50 healthy volun teers and the 40 patients in the study revealed a significantly higher PEP: L VET ratio in the patient gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::956d592000f30e182ce484d4786a6dc2
https://doi.org/10.1007/bf03258284
https://doi.org/10.1007/bf03258284
Publikováno v:
Clinical Science. 61:473s-476s
1. In a double-blind placebo-controlled crossover study a 4 week treatment with ketanserin was shown to reduce systolic and diastolic blood pressure markedly and significantly in 10 patients with essential hypertension. Heart rate remained virtually
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dd58477acbb97b415b75dda83349da2
https://doi.org/10.1042/cs061473s
https://doi.org/10.1042/cs061473s